JP2023552329A5 - - Google Patents

Info

Publication number
JP2023552329A5
JP2023552329A5 JP2023532489A JP2023532489A JP2023552329A5 JP 2023552329 A5 JP2023552329 A5 JP 2023552329A5 JP 2023532489 A JP2023532489 A JP 2023532489A JP 2023532489 A JP2023532489 A JP 2023532489A JP 2023552329 A5 JP2023552329 A5 JP 2023552329A5
Authority
JP
Japan
Prior art keywords
suspension
approximately
dose
paliperidone
palmitate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023532489A
Other languages
English (en)
Japanese (ja)
Other versions
JP7792959B2 (ja
JP2023552329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/062147 external-priority patent/WO2022111859A1/en
Publication of JP2023552329A publication Critical patent/JP2023552329A/ja
Publication of JP2023552329A5 publication Critical patent/JP2023552329A5/ja
Priority to JP2025173295A priority Critical patent/JP2026027255A/ja
Application granted granted Critical
Publication of JP7792959B2 publication Critical patent/JP7792959B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023532489A 2020-11-30 2021-05-07 持続放出パリペリドン注射可能製剤に関連する投与レジメン Active JP7792959B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025173295A JP2026027255A (ja) 2020-11-30 2025-10-15 持続放出パリペリドン注射可能製剤に関連する投与レジメン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119405P 2020-11-30 2020-11-30
US63/119,405 2020-11-30
PCT/EP2021/062147 WO2022111859A1 (en) 2020-11-30 2021-05-07 Dosing regimens associated with extended release paliperidone injectable formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025173295A Division JP2026027255A (ja) 2020-11-30 2025-10-15 持続放出パリペリドン注射可能製剤に関連する投与レジメン

Publications (3)

Publication Number Publication Date
JP2023552329A JP2023552329A (ja) 2023-12-15
JP2023552329A5 true JP2023552329A5 (cg-RX-API-DMAC7.html) 2024-05-17
JP7792959B2 JP7792959B2 (ja) 2025-12-26

Family

ID=75888043

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023532489A Active JP7792959B2 (ja) 2020-11-30 2021-05-07 持続放出パリペリドン注射可能製剤に関連する投与レジメン
JP2025173295A Pending JP2026027255A (ja) 2020-11-30 2025-10-15 持続放出パリペリドン注射可能製剤に関連する投与レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025173295A Pending JP2026027255A (ja) 2020-11-30 2025-10-15 持続放出パリペリドン注射可能製剤に関連する投与レジメン

Country Status (22)

Country Link
US (3) US11304951B1 (cg-RX-API-DMAC7.html)
EP (2) EP4025188B1 (cg-RX-API-DMAC7.html)
JP (2) JP7792959B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250053980A (cg-RX-API-DMAC7.html)
CN (1) CN116583270A (cg-RX-API-DMAC7.html)
AU (3) AU2021386450B2 (cg-RX-API-DMAC7.html)
CA (1) CA3203566A1 (cg-RX-API-DMAC7.html)
DK (1) DK4025188T3 (cg-RX-API-DMAC7.html)
ES (1) ES2973583T3 (cg-RX-API-DMAC7.html)
FI (1) FI4025188T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240074T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065573T2 (cg-RX-API-DMAC7.html)
IL (1) IL303253A (cg-RX-API-DMAC7.html)
LT (1) LT4025188T (cg-RX-API-DMAC7.html)
MX (2) MX2023006366A (cg-RX-API-DMAC7.html)
PL (1) PL4025188T3 (cg-RX-API-DMAC7.html)
PT (1) PT4025188T (cg-RX-API-DMAC7.html)
RS (1) RS65178B1 (cg-RX-API-DMAC7.html)
SI (1) SI4025188T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400077T1 (cg-RX-API-DMAC7.html)
TW (2) TWI877363B (cg-RX-API-DMAC7.html)
WO (1) WO2022111859A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4025188B1 (en) * 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
PL4005555T3 (pl) 2020-11-30 2024-09-02 Janssen Pharmaceutica Nv Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu
SI4025187T1 (sl) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
CN116528836A (zh) 2020-11-30 2023-08-01 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
CA2655335C (en) * 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
AU2010313290A1 (en) * 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
SI2529757T1 (sl) 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
WO2016157061A1 (en) * 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
DK3744326T3 (da) * 2015-04-07 2024-02-05 Janssen Pharmaceutica Nv Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere
CN114783258A (zh) 2015-06-19 2022-07-22 詹森药业有限公司 用于药物施用和混合的系统及用于所述系统的适当技术的训练
US20190183896A1 (en) * 2017-12-14 2019-06-20 SpecGx LLC One step milling process for preparing micronized paliperidone esters
EP4025188B1 (en) * 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations

Similar Documents

Publication Publication Date Title
JP2023552149A5 (cg-RX-API-DMAC7.html)
JP3701870B2 (ja) 末梢血管疾患治療のための9−デオキシ−2’,9−α−メタノ−3−オキサ−4,5,6−トリノール−3,7−(1’,3’−インターフェニ
JP2023551009A5 (cg-RX-API-DMAC7.html)
JP2022539821A5 (cg-RX-API-DMAC7.html)
JPH10511075A (ja) 骨格筋収縮を阻害する酸化窒素種および付加物の使用
JP2023535744A5 (cg-RX-API-DMAC7.html)
FI4025188T3 (fi) Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia
JP2022526763A5 (cg-RX-API-DMAC7.html)
AU618997B2 (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
FI4025189T3 (fi) Viivästetysti vapauttavaan injektoitavaan paliperidoniin liittyviä annostusohjelmia
FI4025187T3 (fi) Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia
EP2116241B1 (en) Pharmaceutical composition
EA004474B1 (ru) Комбинированное лечение заболевания цнс, особенно болезни паркинсона, путём совместного введения каберголина и прамипексола
EP4144360A1 (en) Sars-cov-2 antiviral drug antiprovir
MX2021008208A (es) Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi.
CN111166898B (zh) 锝[99Tc]唑来膦酸在制备治疗骨质疏松药物中的应用
JP2023520703A5 (cg-RX-API-DMAC7.html)
TWI289060B (en) Pharmaceutical composition for improving the recovery of post-stroke patients
JP2022538898A5 (cg-RX-API-DMAC7.html)
KR20210137484A (ko) 캡시드 조립 조절제 고체 제형
US11452710B1 (en) Micronutrient and plant extract composition and method of improving bone health
JP2627914B2 (ja) プロスタグランジン類の選択的作用増強剤
US11364218B2 (en) Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome
EP1518554B1 (en) Pharmaceutical composition for the treatment of hyperhomocysteinemia
JPH0213644B2 (cg-RX-API-DMAC7.html)